Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pasireotide in metastatic carcinoid tumors
NCT00088595Phase 2Completed
- Sponsor
- Novartis
- Start
- Jan 2004
- Primary completion
- Jul 2008
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of pasireotide LAR in Carcinoid Tumor (CT), sponsored by Novartis. Started Jan 2004; status: completed.
02
Drugs
pasireotide LAR
03
Conditions
Carcinoid Tumor (CT)
Beyond the preview
Go deeper on NCT00088595.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00088595.